Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage.

Objective: To evaluate the role of GnRH agonist (GnRH-a) and/or drainage in the management of large endometriomas.

Design: This prospective clinical study was conducted in a parallel and randomized design.

Setting: Department of Gynecology, Cliniques Universitaires St.

Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease.

The safety, pharmacokinetics and efficacy of one daily injection (qd) of amikacin (AK) and netilmicin (NT) was compared with the recommended schedules (cs), i.e. twice-daily or thrice-daily, respectively.

Administration of nasal Buserelin as compared with subcutaneous Buserelin implant for endometriosis.

One hundred infertile patients with laparoscopically confirmed ovarian endometriosis were treated with either intranasal (IN) Buserelin (Hoechst, AG, Frankfurt am Main, West Germany) (300 micrograms three times a day) or subcutaneous (SC) Buserelin implant (6.6 mg Buserelin). Serum estradiol was suppressed in the menopausal range in both groups, but the inhibition of the pituitary ovarian axis appeared more profound and consistent in the SC group than in the IN group.

Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect.

A new diuretic drug, torasemide, after oral or i. v. administration of 20 mg to six normal volunteers showed good bioavailability (greater than 91%).